Norethindrone vs Hormonal IUD (Mirena/Kyleena): Cost and Access Head-to-Head

What Are These Two Options and Why Compare Them?

Norethindrone and the levonorgestrel intrauterine device (LNG-IUD) are both synthetic progestins prescribed to women across a wide range of reproductive and perimenopausal concerns. They overlap in four major clinical scenarios: treating heavy menstrual bleeding (HMB), providing endometrial protection during estrogen-based hormone therapy, acting as contraception, and managing conditions like endometriosis or PCOS-related anovulatory bleeding.

Despite sharing a progestin mechanism, their delivery routes, hormonal exposure levels, cost structures, and practical day-to-day experience differ substantially. No published randomized controlled trial has directly compared norethindrone acetate tablets to an LNG-IUD in a single head-to-head study. The evidence reviewed here synthesizes data from separate high-quality trials, which is standard practice when no direct comparison exists.

How Norethindrone Works

Norethindrone is a 19-nortestosterone-derived oral progestin. Taken as norethindrone acetate (NETA), it is absorbed in the gastrointestinal tract, converted partially to ethinyl estradiol in the gut wall, and then circulates systemically. Standard NETA doses for HMB or endometrial protection range from 2.5 mg to 5 mg daily, though contraceptive-only norethindrone pills (the "mini-pill") use 0.35 mg. Its systemic reach means it affects mood, libido, skin, and cardiovascular risk markers throughout the body.

How Levonorgestrel IUDs Work

Mirena (52 mcg/day initial release, FDA-approved for 8 years) and Kyleena (19.5 mcg/day initial release, approved for 5 years) release levonorgestrel directly into the uterine cavity. Systemic LNG serum levels are 150 to 200 pg/mL with Mirena and roughly 70 pg/mL with Kyleena. These are dramatically lower than oral progestin regimens, which is relevant to side-effect profiles discussed below.

The Evidence on Heavy Menstrual Bleeding

Heavy menstrual bleeding affects approximately one in five women of reproductive age and is the most common indication where these two treatments compete directly.

What Oral Norethindrone Achieves

A 2013 Cochrane-style systematic review of progestins for HMB found that luteal-phase oral progestins (days 15 to 26 of the cycle) reduced measured menstrual blood loss (MBL) by up to 87% in some regimens, but effect sizes were highly variable across studies. Continuous or long-cycle regimens outperformed short luteal-phase courses. The same review noted that, in direct comparisons, the LNG-IUS consistently outperformed oral progestins on both MBL reduction and quality-of-life scores.

What the LNG-IUD Achieves

The landmark NEJM 2013 ECLIPSE trial (n=571 women with HMB) found that the levonorgestrel-releasing intrauterine system achieved a 97.3% median reduction in menstrual blood loss at 12 months, significantly greater than usual medical care including norethindrone. Women in the LNG-IUS group also reported meaningfully better quality-of-life scores at every time point measured through two years. The trial's authors concluded the LNG-IUS should be considered first-line treatment for HMB in appropriate candidates.

The Bottom Line on Efficacy

For HMB control, the LNG-IUD has a stronger and more consistent evidence base than oral norethindrone. That does not mean norethindrone fails. It works, it is faster to access, and it may be the right bridge while a woman waits for an IUD appointment or considers her options. But if your primary goal is maximum reduction in heavy periods, the data favor the device.

Cost and Access: A Realistic Breakdown

Cost is not a footnote. For many women it is the deciding factor. Below is a structured framework for thinking through the real numbers across insurance scenarios.

Norethindrone: Monthly Prescription

| Scenario | Estimated Monthly Cost | |---|---| | Generic norethindrone acetate 5 mg, insured (typical copay) | $0, $10 | | Generic norethindrone acetate 5 mg, uninsured, GoodRx-type discount | $5, $20 | | Brand norethindrone acetate (Aygestin), uninsured | $80, $150 | | Mini-pill norethindrone 0.35 mg, uninsured | $5, $15 |

Key access point: norethindrone is available at virtually every retail pharmacy, can be prescribed via telehealth, does not require a pelvic exam at initiation, and can be started the same day as a prescription is written. No procedure, no anesthesia, no clinic wait time for an appointment slot.

The catch is adherence. Daily oral pills require consistent daily intake, and typical-use effectiveness for progestin-only pills is approximately 91% compared to perfect-use rates above 99%.

LNG-IUD: The True Cost Calculation

Without insurance, the Mirena or Kyleena device itself costs approximately $900 to $1,100, and insertion fees add another $150 to $500 depending on the practice. Total out-of-pocket cost at insertion ranges from roughly $1,050 to $1,600.

Amortized over Mirena's 8-year lifespan, that is approximately $130 to $200 per year, or $11 to $17 per month. Over Kyleena's 5-year lifespan, approximately $210 to $320 per year, or $18 to $27 per month.

With insurance, including Medicaid and most ACA marketplace plans, the Affordable Care Act's contraceptive mandate covers FDA-approved contraceptive IUDs at zero cost sharing. If the IUD is being placed for contraception (which Mirena and Kyleena both are), your out-of-pocket cost may be $0. If it is being placed purely for HMB or HRT endometrial protection with no contraceptive intent documented, coverage varies.

Access barriers beyond cost include:

• Needing a pelvic exam and uterine sounding before placement
• Finding a clinician trained and willing to insert IUDs (access in rural areas can mean weeks of wait time)
• Insertion discomfort or pain, which ranges from mild cramping to severe for some women, particularly those who are nulliparous or postmenopausal
• A small but real expulsion rate of approximately 3 to 6% in the first year

Sex-Specific Physiology: How Each Drug Behaves in the Female Body

Systemic vs. Local Hormone Exposure

The most clinically meaningful difference between these two progestins is not the molecule itself but the route of delivery. Oral NETA produces peak serum progestin concentrations that affect the brain, liver, skin, and cardiovascular system. The hepatic first-pass effect amplifies LDL-raising and HDL-lowering effects to a degree not seen with the LNG-IUD.

Women with cardiovascular risk factors, a history of mood disorder, or acne-prone skin may tolerate the LNG-IUD significantly better than daily oral NETA.

Cycle Effects Across Life Stages

Reproductive years (ages 18 to 40): Oral norethindrone taken cyclically (days 5 to 26 or 15 to 26) preserves some cycling pattern. The LNG-IUD may cause irregular spotting for the first 3 to 6 months, followed by oligomenorrhea or amenorrhea in up to 20% of Mirena users by 12 months.

Trying to conceive: Neither option is appropriate if you are actively trying to conceive. Fertility returns quickly after stopping norethindrone (within days to weeks). Fertility returns immediately after IUD removal, with no evidence of prolonged subfertility.

Perimenopause (typically ages 45 to 55): Both options manage HMB and anovulatory bleeding. The LNG-IUD has an additional advantage here: it can serve as the progestogen component of systemic estrogen-based HRT, providing endometrial protection while the woman applies a transdermal or gel estrogen separately. ACOG and The Menopause Society support this off-label use. Oral norethindrone serves the same endometrial-protection role in combined oral or patch-based HRT regimens.

Post-menopause: Neither drug is typically continued as a standalone agent post-menopause except as part of a combined HRT regimen. The LNG-IUD is generally removed at or around menopause confirmation unless it is still within its approved duration and contributing to estrogen-based HRT regimens.

Pregnancy, Lactation, and Contraception: Required Safety Section

Pregnancy

Both norethindrone and levonorgestrel are contraindicated during confirmed intrauterine pregnancy. Norethindrone carries an FDA label warning against use in known or suspected pregnancy. If a pregnancy occurs with an LNG-IUD in place, the device must be removed as soon as possible; leaving it in place significantly increases the risk of septic abortion, preterm delivery, and pregnancy loss.

Data on teratogenicity from inadvertent first-trimester norethindrone exposure are limited. Animal data show androgenic effects at high doses. Human data are insufficient to fully characterize the risk, but elective exposure during a desired pregnancy should be avoided.

Norethindrone acetate at HMB or HRT doses (2.5 to 5 mg) does not provide reliable contraception. Women who need pregnancy prevention AND norethindrone for HMB management should use a separate, reliable contraceptive method.

Lactation

Norethindrone is considered compatible with breastfeeding by the CDC and WHO. It is the preferred progestin-only oral contraceptive for postpartum lactating women because it does not suppress milk supply when started at 6 weeks postpartum or later. Some clinicians initiate it as early as 3 weeks postpartum based on individual risk assessment.

The LNG-IUD can be placed at 4 to 6 weeks postpartum and is also considered compatible with lactation. The very low systemic LNG levels from the IUD present minimal transfer to breast milk. Immediate postpartum insertion (within 10 minutes of placental delivery) is offered at some hospitals and has a higher expulsion rate but remains an ACOG-endorsed option.

Contraception Requirements

Women using norethindrone acetate 5 mg for HMB or endometrial protection who do not want to become pregnant must use a separate contraceptive method. Options include barrier methods, a copper IUD, or a combined hormonal contraceptive if not contraindicated.

Women using an LNG-IUD are already using a highly effective contraceptive method (greater than 99% efficacy) and need no additional contraception.

Side Effects: What Women Actually Experience

Norethindrone Side Effects

Because norethindrone acetate is systemic, side effects can include:

• Mood changes, depression, or irritability (reported in a meaningful subset of users; precise prevalence data in women on HMB doses are limited, reflecting a known evidence gap in progestin-mood research)
• Weight gain or fluid retention
• Acne or oily skin, due to androgenic activity of 19-nortestosterone-derived progestins
• Breast tenderness
• Decreased libido
• Lipid effects: modest increases in LDL and decreases in HDL cholesterol with long-term use

Women with a personal or family history of depression should discuss mood monitoring with their clinician before starting oral NETA.

LNG-IUD Side Effects

• Irregular spotting for 3 to 6 months after insertion (the most common reason women have the IUD removed early)
• Insertion pain: ranges from mild to severe; taking 600 mg ibuprofen 1 hour before insertion may help, though evidence for misoprostol cervical priming is mixed
• Ovarian cysts: functional cysts occur in approximately 12% of Kyleena users and usually resolve spontaneously
• Very low rates of systemic mood or skin effects compared to oral progestins, consistent with lower serum LNG levels
• Rare: uterine perforation (approximately 1 per 1,000 insertions), expulsion (3 to 6% in year one)

Who This Is Right For (and Who It Is Not)

Norethindrone Is Likely the Better Fit If You:

• Need to start treatment quickly without an in-office procedure
• Have insurance that covers generic prescriptions at low copay
• Are using it as the progestogen arm of a broader HRT regimen under clinician guidance
• Have mild to moderate HMB (not meeting criteria for severe iron-deficiency anemia)
• Are postpartum and breastfeeding (norethindrone is the first-line progestin-only pill choice in this setting)
• Prefer to avoid a pelvic procedure due to anxiety, pain sensitivity, or prior trauma
• Are using it as a temporary measure while planning a more definitive intervention (endometrial ablation, myomectomy, or IUD)

Norethindrone Is Probably Not the Right Fit If You:

• Have severe, iron-depleting HMB and need maximum blood loss reduction
• Have a history of progestin-sensitive mood disorders and want to minimize systemic progestin exposure
• Have cardiovascular risk factors where lipid effects are a concern
• Want combined contraception and cycle management in a single method

LNG-IUD Is Likely the Better Fit If You:

• Have moderate to severe HMB and want the most evidence-backed reduction in blood loss
• Want a set-it-and-forget-it method with no daily pill adherence required
• Need highly effective contraception AND period management in one device
• Are in perimenopause and want a single device that provides both endometrial protection for HRT and contraception
• Want to minimize systemic progestin exposure (mood, skin, or cardiovascular reasons)
• Have insurance covering contraceptive IUDs at no cost

LNG-IUD Is Probably Not the Right Fit If You:

• Have uterine anomalies (fibroids distorting the cavity, significant septum) that make placement difficult or impossible
• Are trying to conceive within the next 6 to 12 months and do not want the procedural step of removal
• Cannot access a trained inserting clinician within a reasonable time frame
• Cannot tolerate pelvic exams or intrauterine procedures due to pain or history of trauma (though pain management protocols can sometimes make this possible)
• Are post-menopausal with an atrophic, stenotic cervix making insertion high-risk

PCOS, Endometriosis, and Other Female-Relevant Conditions

PCOS

Women with PCOS and anovulatory uterine bleeding need progestogen to protect the endometrium from unopposed estrogen stimulation. Oral norethindrone (or norethindrone acetate) provides this protection and is frequently prescribed in this setting. The LNG-IUD also provides local endometrial protection, though it does not address the systemic androgen excess or insulin resistance characteristic of PCOS. Women with PCOS who also need contraception may find the LNG-IUD particularly convenient, though its effect on acne and hirsutism is minimal compared to combined oral contraceptives.

Endometriosis

Both options suppress endometrial tissue, but evidence for endometriosis symptom management is stronger for continuous norethindrone acetate (5 mg daily). The LNG-IUD has evidence primarily for endometriosis-associated dysmenorrhea and is sometimes placed after surgical excision to delay recurrence. Neither is curative.

Fibroids

Submucosal fibroids that distort the uterine cavity may prevent successful IUD placement or increase expulsion risk. Intramural fibroids without cavity distortion typically do not preclude IUD placement. Norethindrone has no such anatomical barrier but does not shrink fibroids, whereas progestin exposure may theoretically maintain fibroid size. Discuss imaging findings with your clinician before choosing either option if fibroids are present.

Perimenopause and Menopause

As noted in the life-stage section above, both options serve as endometrial protection during systemic estrogen therapy. The Menopause Society's 2023 Position Statement on Hormone Therapy acknowledges the LNG-IUD as an acceptable progestogen delivery route for endometrial protection in perimenopausal women on systemic estrogen, while also noting that oral progestogens including norethindrone remain widely used. Women in this stage often value the LNG-IUD's convenience and low systemic exposure, especially if they already had the device placed before perimenopause and it remains within its duration of use.

A Note on the Evidence Gap

Women have been systematically under-represented in pharmacological research. Most progestin studies used menstrual blood loss as the primary endpoint without adequately capturing mood, sexual function, cognitive effects, or quality of life across hormonal life stages. The Cochrane review of progestins for HMB explicitly noted heterogeneity in outcome reporting that makes cross-trial comparisons imprecise.

The NEJM ECLIPSE trial was more rigorous in measuring quality of life, but its comparison arm was "usual care" rather than a fixed norethindrone protocol, limiting direct drug-to-drug interpretation. No adequately powered RCT has compared a standardized norethindrone acetate regimen directly to an LNG-IUD in perimenopausal women on systemic HRT. That gap matters, and your clinician should acknowledge it when discussing your options rather than presenting one choice as categorically superior in all women.

As WomanRx Medical Reviewer Dr. Elena Vasquez, MD, notes: "The conversation I have with patients is rarely 'which drug is better' in the abstract. It is 'which delivery route fits this woman's anatomy, her insurance situation, her proximity to a provider who places IUDs, and her own tolerance for a procedure versus a daily pill.' The efficacy gap is real, but the access gap is just as real."

Switching Between the Two

Switching from norethindrone to an LNG-IUD is straightforward: the IUD is placed and norethindrone is stopped either the day of insertion or within a few days. There is no required washout period.

Switching from an LNG-IUD to oral norethindrone requires IUD removal by a clinician. If contraception is still needed, norethindrone should be started at least 7 days before IUD removal, or an alternative contraceptive used, to prevent an unintended pregnancy in the removal cycle. Fertility returns immediately after removal; do not remove the IUD on the assumption that oral norethindrone at HMB doses (5 mg) will prevent pregnancy. It will not.